Neumora Therapeutics, Inc. (NMRA) earnings
NMRA earnings moved a median of -1.71% by the close. Quarterly and annual NMRA reports and results, each read against the price at its own news timestamp. Back to the NMRA overview →
24 measured NMRA earnings events.
Where these NMRA earnings landedvs 24 measured NMRA earnings reactions
| Middle 50% of NMRA earnings reactions | -6.38% to +0.42% |
|---|---|
| Median reaction (to close) | -1.71% |
| Measured reactions | 24 |
Point-in-time · zero look-ahead
Half of the 24 NMRA earnings events with a measured close landed between -6.38% and +0.42%; 29% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Neumora Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -3.43% | -5.33% | |
| Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | -3.43% | -5.33% | |
| Form 10-Q Neumora Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -1.52% | -7.11% | |
| Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | -0.43% | -16.74% | |
| Form 10-K Neumora Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -6.52% | -10.23% | |
| Form 10-Q Neumora Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.63% | +2.40% | |
| Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | +0.00% | +7.50% | |
| Form 10-Q Neumora Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.81% | -0.60% | |
| Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | +1.81% | -0.60% | |
| Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | Press release | -1.32% | -2.12% | |
| Form 10-Q Neumora Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +5.32% | -1.71% | |
| Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +5.32% | -1.71% | |
| Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 | Press release | +1.56% | +0.57% | |
| Form 10-K Neumora Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.63% | -12.19% | |
| Form 10-Q Neumora Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -0.61% | -6.14% | |
| Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -2.19% | -13.13% | |
| Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 | Press release | +1.41% | +0.00% | |
| Form 10-Q Neumora Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.25% | -1.34% | |
| Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +0.34% | +0.76% | |
| Form 10-Q Neumora Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.21% | -1.88% | |
| Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | +1.93% | +4.92% | |
| Form 10-K Neumora Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.20% | -8.30% | |
| Form 10-Q Neumora Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +1.58% | |
| Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | -1.86% | +0.37% |
Keep exploring
More NMRA: analyst actions → · SEC filings → · NMRA overview →